Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF; Viridian Crashes 38% on TED Data

United Therapeutics' Tyvaso delivers 130.1 mL FVCimprovement in TETON-1, its second Phase 3 win in IPF — filing plans now underway. Plus Viridian's 38% stock crash on REVEAL-1 data, Lilly's $115M upfront AI deal with Insilico Medicine, BridgeBio's 54-month ATTR-CM survivaldata, Biogen's Spinraza HD FDA approval, and CBER untitled letters hitting four major companies.Visit us at www.thepharmacloseout.com Pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Tyvaso, treprostinil, United Therapeutics, IPF, idiopathic pulmonary fibrosis, TETON-1, Viridian Therapeutics, elegrobart, REVEAL-1, thyroid eye disease, Eli Lilly, Insilico Medicine, AI drug discovery, BridgeBio, acoramidis, ATTR-CM, Biogen, Spinraza, nusinersen, SMA, spinal muscular atrophy, Takeda, restructuring, Blackstone, CBER, untitled letters, BMS, Novartis, Gilead, Iovance, Kailera, obesity, GLP-1, Lilly, Amgen